Tenatoprazole
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic (CYP2C19-mediated) |
| Elimination half-life | 4.8 to 7.7 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.120.697 |
| Chemical and physical data | |
| Formula | C16H18N4O3S |
| Molar mass | 346.405 g/mol g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]: 22
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]: 27 and again in 2012.[3]: 17
Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]
See also
References
- ^ DataMonitor. March 2003. Gastrointestinal Disease Update: Digestive Disease Week 2003
- ^ Economic Times. 3 March, 2011. Investors unwilling to forgive Wockhardt, promoter for failings
- ^ a b Mitsubishi Tanabe Pharma State of New Product Development (as of May 8, 2012)
- ^ Mitsubishi Tanabe Pharma FY2007 Interim Financial Results
- ^ Li H et al. H+/K+-ATPase inhibitors: a patent review. Expert Opin Ther Pat. 2013 Jan;23(1):99-111. PMID 23205582